| Literature DB >> 31692815 |
Chengqian Dai1, Shu-Jui Kuo2,3, Sung-Lin Hu2,4, Chun-Hao Tsai2,3, Yuan-Li Huang5, Chien-Chung Huang2,6, Lihong Wang1, Guohong Xu1, Chen-Ming Su7, Chih-Hsin Tang2,5,8.
Abstract
Vascular endothelial growth factor C (VEGF-C) promotes angiogenesis, a prominent feature in rheumatoid synovitis, contributing to the perpetuation of the global burden of rheumatoid arthritis (RA). VEGF-C gene polymorphisms predict the risk of developing various human diseases, such as urothelial cell carcinoma, oral cancer and coronary artery disease. We sought to determine whether single nucleotide polymorphisms (SNPs) of the VEGF-C gene can predict the risk of RA. Our study recruited 210 patients with RA and 373 healthy controls between 2007 and 2015, and performed comparative genotyping for SNPs rs7664413, rs11947611, rs1485766, rs2046463 and rs3775194. In analyses adjusted for potential covariates, we found that compared with subjects with the A/A genotype of SNP rs11947611, those with the A/G genotype were 40% more likely to develop RA (adjusted odds ratio [AOR] 0.61; 95% confidence interval [CI] 0.40 to 0.92; p = 0.02). In addition, subjects lacking the A/A genotype (A/G, G/G) of SNP rs2046463 were more than twice as likely as those with the A/A genotype to require methotrexate (AOR 2.23, 95% CI 1.25 to 3.98; p = 0.01), while those who lacked the G/G genotype (G/C, C/C) in the SNP rs3775194 had a significantly lower risk of requiring prednisolone as compared with those with the G/G genotype (AOR 0.39, 95% CI 0.19 to 0.79; p = 0.01). Our findings suggest that VEGF-C gene polymorphisms might serve as a diagnostic marker and therapeutic target for RA therapy. Pharmacotherapies that modulate the activity of the VEGF-C gene may be promising for RA treatment. © The author(s).Entities:
Keywords: VEGF-C; rheumatoid arthritis; single nucleotide polymorphism
Mesh:
Substances:
Year: 2019 PMID: 31692815 PMCID: PMC6818187 DOI: 10.7150/ijms.34659
Source DB: PubMed Journal: Int J Med Sci ISSN: 1449-1907 Impact factor: 3.738
Demographic characteristics of the study population.
| Variables | Healthy controls (n=373) | RA patients (n=210) | OR | (95% CI) | ||
|---|---|---|---|---|---|---|
| N (%) | N (%) | |||||
| Age (years) (mean ± SD) | 42.08 ± 19.02 | 55.05 ± 11.75 | ||||
| Female | 211 (56.6) | 174 (82.9) | 1 | |||
| Male | 162 (43.4) | 36 (17.1) | 0.27 (0.18 to 0.41) | |||
| seropositive | - | ND | 31 (14.8) | |||
| + | ND | 179 (85.2) | ||||
| - | ND | 45 (21.4) | ||||
| + | ND | 165 (78.6) | ||||
| - | ND | 85 (40.0) | ||||
| + | ND | 126 (60.0) | ||||
| - | ND | 119 (56.7) | ||||
| + | ND | 91 (43.3) | ||||
| - | ND | 114 (54.3) | ||||
| + | ND | 96 (45.7) | ||||
| 30.54 ± 24.82 | ||||||
| < 20 | ND | 96 (45.7) | ||||
| ≥ 20 | ND | 114 (54.3) | ||||
| 22.68 ± 82.31 | ||||||
| < 8 | ND | 128 (61.0) | ||||
| ≥ 8 | ND | 82 (39.0) | ||||
| RA duration, months (mean ± SD) | ND | 53.73 ±68.58 | ||||
RA = rheumatoid arthritis; OR= odds ratio; CI = confidence interval; RF = rheumatoid factor; ACPA = anti-citrullinated protein antibodies; ND = not determined; ESR = erythrocyte sedimentation rate; CRP = C-reactive protein.
VEGF-C genotyping frequencies in cases and controls and the association with risk of RA.
| Variables | Control(n=373) | Case(n=210) | OR | (95% CI) | AORa | (95% CI) | HWEb | ||
|---|---|---|---|---|---|---|---|---|---|
| N (%) | N (%) | ||||||||
| 0.03/0.98 | |||||||||
| CC | 182 (48.8) | 98 (46.7) | 1 | 1 | |||||
| CT | 141 (37.8) | 92 (43.8) | 1.21 | (0.85-1.74) | 0.29 | 1.25 | (0.83-1.90) | 0.25 | |
| TT | 50 (13.4) | 20 (9.5) | 0.74 | (0.42-1.32) | 0.31 | 0.56 | (0.29-1.07) | 0.08 | |
| CT+TT | 191 (51.2) | 112 (53.33) | 1.09 | (0.78-1.53) | 0.62 | 1.04 | (0.71-1.53) | 0.84 | |
| 0.95/0.10 | |||||||||
| AA | 161 (43.2) | 110 (52.4) | 1 | 1 | |||||
| AG | 166 (44.5) | 75 (35.7) | |||||||
| GG | 46 (12.3) | 25 (11.9) | 0.8 | (0.46-1.37) | 0.41 | 0.74 | (040-1.39) | 0.34 | |
| AG+GG | 212 (56.8) | 100 (47.6) | 0.69 | (0.49-0.97) | 0.03 | 0.64 | (0.43-0.94) | 0.03 | |
| 0.47/0.06 | |||||||||
| GG | 111 (29.8) | 47 (22.4) | 1 | 1 | |||||
| GT | 174 (46.6) | 104 (49.5) | 1.12 | (0.76-1.68) | 0.56 | 0.98 | (0.62-1.55) | 0.93 | |
| TT | 88 (23.6) | 59 (28.1) | 1.01 | (0.63-1.62) | 0.98 | 1.06 | (0.62-1.81) | 0.86 | |
| GT+TT | 262 (70.24) | 151 (71.9) | 1.08 | (0.75-1.58) | 0.67 | 1.01 | (0.66-1.54) | 0.98 | |
| 0.03/0.82 | |||||||||
| AA | 181 (48.5) | 94 (44.8) | 1 | 1 | |||||
| AG | 141 (37.8) | 96 (45.7) | 1.31 | (0.92-1.88) | 0.34 | 1.35 | (0.89-2.05) | 0.15 | |
| GG | 51 (13.7) | 20 (9.5) | 0.76 | (0.43-1.34) | 0.14 | 0.57 | (0.30-1.10) | 0.09 | |
| AG+GG | 192 (51.5) | 116 (55.2) | 1.16 | (0.83-1.63) | 0.38 | 1.11 | (0.76-1.64) | 0.59 | |
| 0.99/0.97 | |||||||||
| GG | 311 (83.4) | 168 (80.0) | 1 | 1 | |||||
| CG | 59 (15.8) | 40 (19.0) | 1.26 | (0.81-1.96) | 0.32 | 1.38 | (0.82-2.32) | 0.22 | |
| CC | 3 (0.8) | 2 (1.0) | 1.23 | (0.20-7.46) | 0.82 | 1.17 | (0.17-7.96) | 0.87 | |
| CG+CC | 62 (16.6) | 42 (20.0) | 1.25 | (0.81-1.94) | 0.31 | 1.37 | (0.83-2.27) | 0.22 |
a Logistic regression with adjustment for age, gender. b Control/Case Hardy-Weinberg equilibrium test.
The association with VEGF-C genotyping frequencies and age onset of RA.
| Age-onset < 35 years | OR (95 % CI) | AORa (95% CI) | ||||
|---|---|---|---|---|---|---|
| (n=185) N(%) | (n=25) N(%) | |||||
| Age, year (mean±SD) | 39.28± 11.77 | 57.18 ± 10.02 | < 0.0001 | |||
| CC | 82 (44.3) | 16 (64.0) | 1 | 1 | ||
| CT | 85 (46.0) | 7 (28.0) | ||||
| TT | 18 (9.7) | 2 (8.0) | 0.57 (0.12-2.70) | 0.48 | 0.4(0.06-2.67) | 0.34 |
| CT+TT | 103 (55.7) | 9 (36.0) | ||||
| AA | 101 (54.6) | 9 (36.0) | 1 | 1 | ||
| AG | 64 (34.6) | 11 (44.0) | ||||
| GG | 20 (10.8) | 5 (20.0) | 2.81(0.85-9.26) | 0.09 | 3.16(0.61-16.46) | 0.17 |
| AG+GG | 84 (45.4) | 16 (64.0) | ||||
| GG | 55 (29.7) | 4 (16.0) | 1 | 1 | ||
| GT | 93 (50.3) | 11 (44.0) | 1.63(0.49-5.36) | 0.42 | 2.28(0.53-9.82) | 0.27 |
| TT | 37 (20.0) | 10 (40.0) | 3.72(1.08-12.70) | 0.04 | 3.67(0.80-16.96) | 0.09 |
| GT+TT | 130 (70.3) | 151 (71.9) | 2.22(0.73-6.77) | 0.16 | 2.79(0.71-10.93) | 0.14 |
| AA | 78 (42.2) | 16 (64.0) | 1 | 1 | ||
| AG | 89 (48.1) | 7 (28.0) | 0.38(0.15-0.98) | 0.04 | 0.2(0.05-0.74) | 0.02 |
| GG | 18 (9.7) | 2 (8.0) | 0.54(0.11-0.57) | 0.44 | 0.38(0.05-0.60) | 0.33 |
| AG+GG | 107 (57.8) | 9 (36.0) | 0.41(0.17-0.98) | 0.04 | 0.23(0.07-0.76) | 0.02 |
| GG | 146 (78.9) | 22 (88.0) | 1 | 1 | ||
| CG | 37 (20.0) | 3 (12.0) | 0.54(0.15-1.89) | 0.33 | 0.44(0.09-2.18) | 0.32 |
| CC | 2 (1.1) | 0 (0.0) | ||||
| CG+CC | 39 (21.1) | 2 (12.0) | 0.51(0.15-1.79) | 0.29 | 0.39 | 0.24 |
a Logistic regression with adjustment for age, gender.
Clinical biochemical status and VEGF‐C rs11947611 genotypic frequencies in RA Patients*
| Variables | AA (n=110) | AG+GG (n=100) | OR (95% CI) | AORa(95% CI) | |||
|---|---|---|---|---|---|---|---|
| N (%) | N (%) | ||||||
| Negative | 16 (14.5) | 15 (15.0) | 1 | 1 | |||
| Positive | 94 (85.5) | 85 (85.0) | 0.97(0.45-2.07) | 0.93 | 0.97(0.45-2.09) | 0.94 | |
| Negative | 25 (22.7) | 20 (20.0) | 1 | ||||
| Positive | 85 (77.3) | 80 (80.0) | 1.18(0.61-2.28) | 0.63 | 1.15(0.59-2.25) | 0.67 | |
| < 20 | 50 (45.5) | 46 (46.0) | 1 | 1 | |||
| ≥ 20 | 60 (54.5) | 54 (54.0) | 0.98(0.57-1.69) | 0.94 | 0.97(0.56-1.68) | 0.92 | |
| < 8 | 65 (59.1) | 63 (63.0) | 1 | 1 | |||
| ≥ 8 | 45 (40.9) | 37 (37.0) | 0.85(0.49-1.48) | 0.56 | 0.86(0.49-1.51) | 0.6 | |
*RF= rheumatoid factor; ACPA= anti-citrullinated protein antibodies; ESR= erythrocyte sedimentation rate; CRP= C-reactive protein; a Logistic regression with adjustment for age, gender.
The association with VEGF-C genotyping frequencies and RA medication.
| Variables | N (%) | N (%) | OR (95% CI) | AORa (95% CI) | |||
|---|---|---|---|---|---|---|---|
| Anti-TNF | - | 53 (54.1) | 73 (65.2) | 1 | 1 | ||
| + | 45 (45.9) | 39 (34.8) | 0.63(0.36-1.10) | 0.1 | 0.65(0.37-1.14) | 0.13 | |
| Methotrexate | - | 51 (52.0) | 40 (35.7) | 1 | 1 | ||
| + | 47 (48.0) | 72 (64.3) | |||||
| Prednisolone | - | 49 (50.0) | 47 (42.0) | 1 | 1 | ||
| + | 49 (50.0) | 65 (58.0) | 1.38(0.80-2.34) | 0.24 | 1.36(0.78-2.35) | 0.28 | |
| Anti-TNF | - | 50 (53.2) | 76 (65.5) | 1 | 1 | ||
| + | 44 (46.8) | 40 (34.5) | 0.60(0.34-1.04) | 0.07 | 0.62(0.36-1.10) | 0.1 | |
| Methotrexate | - | 50 (53.2) | 41 (35.3) | 1 | 1 | ||
| + | 44 (46.8) | 75 (64.7) | |||||
| Prednisolone | - | 48 (51.1) | 48 (41.4) | 1 | 1 | ||
| + | 46 (48.9) | 68 (58.6) | 1.48(0.86-2.56) | 0.16 | 1.44(0.83-2.49) | 0.2 | |
| Anti-TNF | - | 102 (60.7) | 24 (57.1) | 1 | 1 | ||
| + | 66 (39.3) | 18 (42.9) | 1.15(0.58-2.30) | 0.67 | 1.13(0.57-2.27) | 0.73 | |
| Methotrexate | - | 74 (44.1) | 17 (40.5) | 1 | 1 | ||
| + | 94 (55.9) | 25 (59.5) | 1.16(0.57-2.30) | 0.68 | 1.27(0.62-2.59) | 0.51 | |
| Prednisolone | - | 69 (41.1) | 27 (64.3) | 1 | 1 | ||
| + | 99 (58.9) | 15 (35.7) | |||||
a Logistic regression with adjustment for age, gender.